Eric Meissner to Middle Aged
This is a "connection" page, showing publications Eric Meissner has written about Middle Aged.
Connection Strength
0.327
-
Association of Substance Use With Hospitalization and Virologic Suppression in a Southern Academic HIV Clinic. Am J Med Sci. 2018 06; 355(6):553-558.
Score: 0.042
-
Across state lines: Fulminant Babesia microti infection in a liver transplant recipient. Transpl Infect Dis. 2017 Oct; 19(5).
Score: 0.041
-
Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int. 2016 12; 36(12):1783-1792.
Score: 0.038
-
Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis. J Viral Hepat. 2016 07; 23(7):496-505.
Score: 0.037
-
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology. 2015 Mar; 61(3):790-801.
Score: 0.034
-
IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling. J Immunol. 2017 12 01; 199(11):3808-3820.
Score: 0.010
-
Pathological Role of Anti-CD4 Antibodies in HIV-Infected Immunologic Nonresponders Receiving Virus-Suppressive Antiretroviral Therapy. J Infect Dis. 2017 07 01; 216(1):82-91.
Score: 0.010
-
Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. Biomed Res Int. 2017; 2017:2067479.
Score: 0.010
-
Effects of ribavirin/sofosbuvir treatment and ITPA phenotype on endogenous purines. Antiviral Res. 2017 02; 138:79-85.
Score: 0.010
-
Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels. J Clin Pharmacol. 2017 01; 57(1):118-124.
Score: 0.009
-
Elevated hepatic lipid and interferon stimulated gene expression in HCV GT3 patients relative to non-alcoholic steatohepatitis. Hepatol Int. 2016 Nov; 10(6):937-946.
Score: 0.009
-
Key differences in B cell activation patterns and immune correlates among treated HIV-infected patients versus healthy controls following influenza vaccination. Vaccine. 2016 Apr 07; 34(16):1945-55.
Score: 0.009
-
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration. AIDS Res Hum Retroviruses. 2016 May; 32(5):456-62.
Score: 0.009
-
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial. Ann Intern Med. 2015 Dec 15; 163(12):899-907.
Score: 0.009
-
Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. J Antimicrob Chemother. 2015 Aug; 70(8):2322-9.
Score: 0.009
-
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31; 313(12):1232-9.
Score: 0.009
-
Persistently elevated abnormal B-cell subpopulations and anti-core antibodies in patients co-infected with HIV/HCV who relapse. J Med Virol. 2015 Apr; 87(4):544-52.
Score: 0.009
-
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet. 2015 Mar 21; 385(9973):1107-13.
Score: 0.008
-
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014 Nov 04; 161(9):634-8.
Score: 0.008
-
Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013 Aug 28; 310(8):804-11.
Score: 0.008